Skip to content
Home/Companies/Biotech/Aprea

Aprea

Biotech·Sweden·Exited 2019·Held 3yr
Entry
2016
Hold
3yr
Exit
2019

Who owns Aprea?

Aprea was owned by HealthCap through HealthCap VII (2016 vintage) from 2016 to 2019, exited via IPO.

Hand-verified · updated 2026-08-18

HealthCap
Investor
HealthCap
HealthCap VII · 2016 · VC

Key facts

HQSweden
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2019

More from HealthCap VII

Other portfolio companies in the same fund.

Mahzi Therapeutics
Active
BiotechUS· 2020
Priothera Ltd.
Active
BiotechIreland· 2020
SynOx Therapeutics Ltd
Active
BiotechIreland· 2020
Carisma Therapeutics
Exited 2023
BiotechUS· 2018
to
InCarda Therapeutics Inc.
Active
BiotechUS· 2018
Modus Therapeutics
Modus Therapeutics
Active
BiotechSweden· 2018

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Aprea

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Aprea?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Aprea.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue